Keratin-based drug carriers are responsible for the targeted delivery of drugs for treatment of cancer by binding to specific vitronectin integrin receptors that are highly expressed by cancer cells due to the specific sequence of amino acids arginine-glycine-aspartic acid (RGD) and leucine-aspartic acid-valine (LDV) [112]. Here, VTN is linked to cancer.